These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 18283075

  • 1. Interim futility analysis with intermediate endpoints.
    Goldman B, LeBlanc M, Crowley J.
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [Abstract] [Full Text] [Related]

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM.
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [Abstract] [Full Text] [Related]

  • 3. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H, Bretz F, Racine-Poon A.
    Stat Med; 2007 Nov 30; 26(27):4925-38. PubMed ID: 17590875
    [Abstract] [Full Text] [Related]

  • 4. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y, Grambsch PM, Neaton JD.
    Clin Trials; 2007 Nov 30; 4(2):140-53. PubMed ID: 17456513
    [Abstract] [Full Text] [Related]

  • 5. Assessment of futility in clinical trials.
    Snapinn S, Chen MG, Jiang Q, Koutsoukos T.
    Pharm Stat; 2006 Nov 30; 5(4):273-81. PubMed ID: 17128426
    [Abstract] [Full Text] [Related]

  • 6. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM.
    Stat Med; 2006 Oct 15; 25(19):3348-65. PubMed ID: 16345019
    [Abstract] [Full Text] [Related]

  • 7. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q, Freidlin B, Korn EL, Halabi S, Mandrekar S, Dignam JJ.
    Clin Trials; 2017 Feb 15; 14(1):48-58. PubMed ID: 27590208
    [Abstract] [Full Text] [Related]

  • 8. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials.
    J Natl Cancer Inst; 2008 May 21; 100(10):698-711. PubMed ID: 18477802
    [Abstract] [Full Text] [Related]

  • 9. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K, Jung SH.
    Clin Trials; 2008 May 21; 5(3):209-21. PubMed ID: 18559409
    [Abstract] [Full Text] [Related]

  • 10. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
    Hughes S, Cuffe RL, Lieftucht A, Garrett Nichols W.
    Pharm Stat; 2009 May 21; 8(1):25-37. PubMed ID: 18383194
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Flexible two-stage design with sample size reassessment for survival trials.
    Desseaux K, Porcher R.
    Stat Med; 2007 Nov 30; 26(27):5002-13. PubMed ID: 17577242
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls.
    Fay MP, Huang CY, Twum-Danso NA.
    Clin Trials; 2007 Nov 30; 4(6):598-610. PubMed ID: 18042569
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ, Feng L.
    J Clin Oncol; 2005 Jul 01; 23(19):4450-7. PubMed ID: 15994154
    [Abstract] [Full Text] [Related]

  • 17. Increasing the sample size when the unblinded interim result is promising.
    Chen YH, DeMets DL, Lan KK.
    Stat Med; 2004 Apr 15; 23(7):1023-38. PubMed ID: 15057876
    [Abstract] [Full Text] [Related]

  • 18. Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.
    Hong S, Shi L.
    Stat Med; 2012 Apr 30; 31(9):831-43. PubMed ID: 22302442
    [Abstract] [Full Text] [Related]

  • 19. Adaptive designs for confirmatory clinical trials.
    Bretz F, Koenig F, Brannath W, Glimm E, Posch M.
    Stat Med; 2009 Apr 15; 28(8):1181-217. PubMed ID: 19206095
    [Abstract] [Full Text] [Related]

  • 20. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM, Younes N.
    Stat Med; 2007 Nov 30; 26(27):5014-32. PubMed ID: 17577245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.